Parameters of ‘peroxidation — antioxidant defense’ system and platelet–derived growth factor level in endocrine ophthalmopathy in the course of glucocorticoid pulse therapy

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

INTRODUCTION: Endocrine ophthalmopathy (EO) is a multifactorial autoimmune disease, with the need of further study of immunological and biochemical pathogenetic factors of this disease.

AIM: To assess the levels of thiobarbituric acid reactive substances (TBARS), total antioxidant activity, and the BB isoform of platelet–derived growth factor (PDGF-BB) in patients with EO in the course of glucocorticoid pulse therapy.

MATERIALS AND METHODS: A total of 30 individuals were examined, from which 2 groups were formed: a control group (n = 15) and a clinical group of patients with an active phase of EO before and after glucocorticoid pulse therapy (n = 15). A comparative clinical and laboratory analysis was conducted that included a comprehensive ophthalmological examination, determination of TBARS level, of the total antioxidant activity and PDGF-BB in blood serum.

RESULTS: TBARS concentration in the EO group before glucocorticoid pulse therapy exceeded values of the control group (р < 0.001) and did not differ from the parameters after treatment (р = 0.683). The total antioxidant activity before treatment was reduced compared to the control (р < 0.001) and also had no significant differences with the parameters after treatment (р = 0.345). The level of PDGF-BB in the active phase of EO before pulse therapy 2.3 times exceeded that of the control group (р < 0.001), 1.5 times decreased with pulse therapy (р < 0.001), but remained 1.6 times (р = 0.008) the control. Statistically significant relationships were found between the content of PDGF-BB and parameters of ‘peroxidation — antioxidant defense’ system (p < 0.001).

CONCLUSION: In patients with EO in the active phase, an imbalance in the ‘peroxidation — antioxidant defense’ system was found in terms of increased production of TBARS. In the course of glucocorticoid pulse therapy, the identified imbalance persisted. In the active phase of the disease, a significant increase in the level of PDGF-BB was detected, with the concentration remaining elevated after treatment. Correlations were established between the parameters of oxidative stress and the level of PDGF-BB. In view of the obtained data, it seems necessary to develop and introduce the alternative treatment methods for EO targeted at trigger points in the pathogenesis of this disease.

全文:

受限制的访问

作者简介

Elizaveta Taskina

Chita State Medical Academy

编辑信件的主要联系方式.
Email: Taskins@yandex.ru
ORCID iD: 0000-0002-6223-8888
SPIN 代码: 5687-2122

MD, Cand. Sci. (Med.)

俄罗斯联邦, Chita

Svetlana Kharintseva

Chita State Medical Academy

Email: s.v.19.28@mail.ru
ORCID iD: 0000-0002-8899-5465
SPIN 代码: 6788-2110

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Chita

Tatyana Karavaeva

Chita State Medical Academy

Email: KaTany1@yandex.ru
ORCID iD: 0000-0002-0487-6275
SPIN 代码: 5483-1547

MD, Cand. Sci. (Med.), Associate Professor

俄罗斯联邦, Chita

参考

  1. Zheng J, Duan H, You S, et al. Research progress on the patho-genesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes. Front Immunol. 2022;13:952954. doi: 10.3389/fimmu.2022.952954
  2. Mishra S, Maurya VK, Kumar S, et al. Clinical management and therapeutic strategies for the Thyroid-Associated ophthalmopathy: current and future perspectives. Curr Eye Res. 2020;45(11):1325–41. doi: 10.1080/02713683.2020.1776331
  3. Hoang TD, Stocker DJ, Chou EL, et al. Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022;51(2):287–304. doi: 10.1016/j.ecl.2021.12.004
  4. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–67. doi: 10.1530/eje-21-0479
  5. Längericht J, Krämer I, Kahaly GJ. Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab. 2020;11:2042018820958335. doi: 10.1177/2042018820958335
  6. Tregubova NV. The role of lipid peroxidation in inflammation. Newsletter of North-Caucasus Federal University. 2013;(2):101–5. (In Russ).
  7. Ma C, Li H, Lu S, et al. Thyroid-associated ophthalmopathy: the role of oxidative stress. Front Endocrinol (Lausanne). 2024;15:1400869. doi: 10.3389/fendo.2024.1400869
  8. Hou T–Y, Wu S–B, Kau H–C, et al. The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy. Biomedicines. 2021;9(12):1871. doi: 10.3390/biomedicines9121871
  9. Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88. doi: 10.1016/j.mam.2017.11.007
  10. Van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2012;97(3):E400–8. doi: 10.1210/jc.2011-2697
  11. Andrae J, Gallini R, Betsholtz C. Role of platelet–derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–312. doi: 10.1101/gad.1653708
  12. Virakul S, Dalm VASH, Paridaens D, et al. Platelet–derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts. Invest Ophthalmol Vis Sci. 2015;56(9):5457–64. doi: 10.1167/iovs.15-17001
  13. Lee J–Y, Yun M, Paik J–S, et al. PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21. Invest Ophthalmol Vis Sci. 2016;57(3):908–13. doi: 10.1167/iovs.15-18157
  14. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37(5):970–80. doi: 10.1016/s0272-6386(05)80013-7
  15. Alekseyev VV, Alipov AN, Andreyev VA, et al.; Karpishchenko AI, editor. Meditsinskiye laboratornyye tekhnologii. Rukovodstvo po klinicheskoy i laboratornoy diagnostike. 3rd ed. Moscow: GEOTAR-Media; 2013. Vol. 2. (In Russ).
  16. Promyslov MSh, Demchuk ML. A modified method of determination of the total serum antioxidant activity. Vopr Med Khim. 1990;36(4):90–2. (In Russ).
  17. Taskina ES, Charinzeva SV. The role of interleukins 17, 23 and antibodies to the thyroid-stimulating hormone receptor in the pathogenesis of endocrine ophthalmopathy. Clinical and Experimental Thyroidology. 2018;14(2):72–80. (In Russ). doi: 10.14341/ket9703
  18. Castaldo M, Zollo C, Esposito G, et al. NOX2-Dependent Reactive Oxygen Species Regulate Formyl-Peptide Receptor 1-Mediated TrkA Transactivation in SH-SY5Y Cells. Oxid Med Cell Longev. 2019;2019: 2051235. doi: 10.1155/2019/2051235
  19. Fan X, Wu J, Yang H, et al. Paeoniflorin blocks the proliferation of vascular smooth muscle cells induced by platelet–derived growth factor BB through ROS mediated ERK1/2 and p38 signaling pathways. Mol Med Rep. 2018;17(1):1676–82. doi: 10.3892/mmr.2017.8093
  20. Galgoczi E, Katko M, Papp FR, et al. Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves' Orbitopathy. Molecules. 2022;28(1):15. doi: 10.3390/molecules28010015

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Correlation relationship between the level of TBARS and PDGF-BB in the group of patients with endocrine ophthalmopathyy. Notes: TBARS — thiobarbituric acid reactive substance, PDGF-BB — platelet–derived growth factor-BB.

下载 (70KB)
索引源数据
3. Fig. 2. Correlation relationship between the level of TAA and PDGF-BB in the group of patients with endocrine ophthalmopathy. Notes: TAA — total antioxidant activity; PDGF-BB — platelet–derived growth factor-BB.

下载 (131KB)
索引源数据
4. Fig. 1. Correlation relationship between the level of TBARS and PDGF-BB in the group of patients with endocrine ophthalmopathyy. Notes: TBARS — thiobarbituric acid reactive substance, PDGF-BB — platelet–derived growth factor-BB.

下载 (75KB)
索引源数据
5. Fig. 2. Correlation relationship between the level of TAA and PDGF-BB in the group of patients with endocrine ophthalmopathy. Notes: TAA — total antioxidant activity; PDGF-BB — platelet–derived growth factor-BB.

下载 (70KB)
索引源数据

版权所有 © Eco-Vector, 2025


Media Registry Entry of the Federal Service for Supervision of Communications, Information Technology and Mass Communications (Roskomnadzor) PI No. FS77-76803 dated September 24, 2019.